CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients

Cancer Genetics and Cytogenetics

Volumn 142, Issue 1, 2003, Pages 21-24

  Gonzalez Gomez, Pilar ^a   Bello, M Josefa ^a   Arjona, Dolores ^a   Alonso, M Eva ^a   Lomas, Jesus ^a   Amiñoso, Cinthia ^a   De Campos, Jose M ^b   Sarasa, Jose L ^c   Gutierrez, Manuel ^a   Rey, Juan A ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; PROTEIN P14; PROTEIN P73; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

AGED; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DAPK GENE; FEMALE; GENE; GENE INACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENCE; LYMPHOMA; MALE; METHYLATION; MGMT GENE; PRIORITY JOURNAL; PROMOTER REGION; RBI GENE; TP53 GENE;

AGED; APOPTOSIS REGULATORY PROTEINS; BRAIN; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CENTRAL NERVOUS SYSTEM NEOPLASMS; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GENES, P53; GENES, TUMOR SUPPRESSOR; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOCOMPETENCE; ISOENZYMES; LYMPHOMA; MALE; MIDDLE AGED; NUCLEAR PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER REGIONS (GENETICS); REFERENCE VALUES; RETINOBLASTOMA PROTEIN; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEINS;

EID: 0037379063     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(02)00799-9     Document Type: Article

References (37)

1. Paulus W., Jellinger K., Morgello S., Deckert-Schlüter M. Malignant lymphomas. Kleihues P., Cavenee W.K. Pathology and genetics of tumors of the nervous system. World health organization classification of tumours. 2000;198-203 IARC Press, Lyon.
2. Grant J.W., Isaacson P.G. Primary central nervous system lymphoma. Brain Pathol. 2:1992;97-109.
3. Yamada K., Yoshioka M., Oami H. A 14q+ marker and a late replicating chromosome #22 in a brain tumor. J Natl Cancer Inst. 59:1977;1193-1195.
4. Miyoshi I., Kubonishi I., Yoshimoto S., Hikita T., Dabasaki H., Tanaka T. Characteristics of a brain lymphoma cell line derived from primary intracranial lymphoma. Cancer. 49:1982;456-459.
5. Itoyama T., Sadamori N., Tsutsumi K., Tokunaga Y., Soda H., Tomonaga M., Yamamori S., Masuda Y., Oshima K., Kikuchi M. Primary central nervous system lymphomas. Immunophenotypic, virologic, and cytogenetic findings of three patients without immune defects. Cancer. 73:1994;455-463.
6. Zattara-Cannoni H., Horshowski N., Figarella-Branger D., Dufour H., Grisoli F., Vagner-Capodano A.M. Unusual chromosome abnormalities in primary central nervous system lymphoma. Leuk Lymphoma. 21:1996;515-517.
7. Bello M.J., de Campos J.M., Kusak M.E., Sarasa J.L., Rey J.A. Deletion 6q and +X, in one primary central nervous system lymphoma (PCNSL) arising in a patient without immune defects. Rev Oncologia. 4:2002;213-214.
8. Rickert C.H., Dockhorn-Dworniczak B., Simon R., Paulus W. Chromosomal imbalances in primary lymphomas of the central nervous system. Am J Pathol. 155:1999;1445-1451.
9. Weber T., Weber R.G., Kaulich K., Actor B., Meyer-Puttlitz B., Lampel S., Buschges R., Weigel R., Deckert-Schluter M., Schmiedek P., Reifenberger G., Lichter P. Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol. 10:2000;73-84.
10. Harada K., Nishizaki T., Kubota H., Harada K., Suzuki M., Sasaki K. Distinct primary central nervous system lymphoma defined by comparative genomic hibridization and laser scanning cytometry. Cancer Genet Cytogenet. 125:2001;147-150.
11. Cobbers J.M.J.L., Wolter M., Reifenberger J., Ring G.U., Jenssen F., An H., Niederacher D., Schmidt E.E., Ichimura K., Floeth F., Kirsch L., Borchard F., Louis D.N., Collins V.P., Reifenberger G. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol. 8:1998;263-276.
12. Alonso M.E., Bello M.J., Gonzalez-Gomez P., Lomas J., Arjona D., de Campos J.M., Kusak M.E., Sarasa J.L., Isla A., Rey J.A. Mutation analysis of the p73 gene in nonastrocytic brain tumors. Br J Cancer. 85:2001;204-208.
13. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P.J. Alterations in the DNA methylation. a fundamental aspect of neoplasia Adv Cancer Res. 72:1998;141-196.
14. Kleihues P., Kavenee W.K. Pathology and genetics of nervous system tumors. World health organization classification of tumours. 2000;IARC Press, Lyon.
15. Rey J.A., Bello M.J., Jimenez-Lara A., Vaquero J., Kusak M.E., de Campos J.M., Sarasa J.L., Pestaña A. Loss of heterozygosity for distal markers on 22q in human gliomas. Int J Cancer. 51:1992;703-706.
16. Herman J.G., Graff J.R., Myohannen S., Nelkin B.D., Baylin B.D. Methylation-specific PCR. a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci USA. 93:1996;9821-9826.
17. Frühwald M.C., O'Dorisio M.S., Dai Z., Tanner S.M., Balster D.A., Gao X., Wright F.A., Plass C. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas - Implication for tumors biology and potential clinical utility. Oncogene. 20:2001;5033-5042.
18. Zöchbauer-Müller S., Fong K.M., Virmani A.K., Geradts J., Gazdar A.F., Minnan J.D. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 61:2001;249-255.
19. INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res. 5:1999;2704-2713.
20. Kang G.H., Shim Y.-H., Jung H.-Y., Kim W.H., Ro J.Y., Rhyu M.-G. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 61:2001;2847-2851.
21. Corn P.G., Kuerbitz S.J., van Noesel M.M., Esteller M., Compitello N., Baylin S.B., Herman J.G. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res. 59:1999;3352-3356.
22. Simpson D.J., Hibberts N.A., McNicol A.M., Clayton R.N., Farrell W.E. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res. 60:2000;1211-1216.
23. Gonzalez-Gomez P., Bello M.J., Alonso M.E., Arjona D., Lomas J., de Campos J.M., Isla A., Rey J.A. CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br J Cancer. in press:2003.
24. Gonzalez-Gomez P., Bello M.J., Arjona D., Lomas J., Alonso M.E., de Campos J.M., Vaquero J., Isla A., Gutierrez M., Rey J.A. Promoter hypermethylation of multiple genes in astrocytic gliomas. Int J Oncology. in press:2003.
25. Weide R., Tiemann M., Pflüger K.H., Koppler H., Parvizl B., Wacker H.H., Kreipe H.H., Havemann K., Parwaresch M.R. Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin's lymphomas. Leukemia. 8:1994;97-101.
26. Koga H., Zhang S.J., Ichikawa T., Washiyama K., Kuroiwa T., Tanaka R., Kumanishi T. Primary malignant lymphoma of the brain. demonstration of the p53 gene mutation by PCR-SSCP analysis and immunohistochemistry Brain Tumor Pathol. 11:1994;151-155.
27. Kawano S., Miller C.W., Gombart A.F., Bartram C.R., Matsuo Y., Asou H., Sakashita A., Said J., Tatsumi E., Koeffler H.P. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood. 94:1999;1113-1120.
28. Siu L.L.P., Chan J.K.C., Wong K.-F., Kwong Y.-L. Specific patterns of gene methylation in natural killer cell lymphomas. P73 is consistently involved. Am J Pathol. 160:2002;59-66.
29. 6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst. 94:2002;26-32.
30. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., Baylin S.B., Herman J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 343:2000;1350-1354.
31. Daniel V. Glutathione S-transferases. Gene structure and regulation of expression. Crit Rev Biochem Mol Biol. 28:1993;173-207.
32. Borde-Chiche P., Diedericha M., Morceau F., Puga A., Wellman M., Dicato M. Regulation of transcription of the glutathione-S-transferase P1 gene by methylation of the minimal promoter in human leukemia cells. Biochem Pharmacol. 61:2001;605-612.
33. Sarmanova J., Benesova K., Gut I., Nedelcheva-Kristensen V., Tynkova L., Soucek P. Genetic polymorphisms of biotransformation enzymes in patients with non-Hodgkin's lymphomas. Hum Mol Genet. 10:2001;1265-1273.
34. Kissil J.L., Feinstein E., Cohen O., Jones P.A., Tsai Y.C., Knowles M.A., Eydmann M.E., Kimchi A. DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines. possible implications for role as tumor suppressor gene Oncogene. 15:1997;403-407.
35. Roberts D.D. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J. 10:1996;1183-1191.
36. Bachman K.E., Herman J.G., Corn P.G., Merlo P.G., Costello J.F., Cavenee W.K., Baylin S.B., Graff J.R. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Res. 59:1999;798-802.
37. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 61:2001;3225-3229.